Jade Biosciences, Inc. — Investor Relations & Filings
Filings indexed
458
across all filing types
Latest filing
2026-06-01
Regulatory Filings
Country
US
United States of America
Listing
US
JBIO
Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, inflammation, and immunology. The company aims to create transformative, disease-modifying treatments to address significant unmet medical needs and redefine the standard of care. Its pipeline features novel biologics, with the lead candidate, JADE101, being developed for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is an inhibitor of the cytokine APRIL (A PRoliferation-Inducing Ligand). The company's programs are based on discovery-stage assets licensed from Paragon Therapeutics.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-06-01 | English | |
| 424B3 | 2026-05-15 | English | |
| S-8 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | |
| 424B3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47917448 | 8-K | 2026-06-01 | English | ||
| 46362227 | 424B3 | 2026-05-15 | English | ||
| 43597502 | S-8 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 43589318 | S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 43582556 | S-3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 43524504 | 424B3 - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-05-07 | English | ||
| 35226913 | 8-K - Jade Biosciences, Inc. (0001798749) (Filer) | 2026-04-22 | English | ||
| 31760251 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31760104 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31760021 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31760250 | 4 Filing | 2026-02-13 | English | ||
| 31760064 | 4 Filing | 2026-02-13 | English | ||
| 31760005 | 4 Filing | 2026-02-13 | English | ||
| 31759976 | 4 Filing | 2026-02-13 | English | ||
| 31759919 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMAGION BIOSYSTEMS LIMITED
Develops nanoparticle-based imaging for non-invasive cancer…
|
IBX | AU | Professional, scientific and te… |
|
IMCB PJSC
Biotechnology company specializing in personal stem cell ba…
|
GEMA | RU | Professional, scientific and te… |
|
Immuneering Corp
Clinical-stage oncology company developing medicines using …
|
IMRX | US | Professional, scientific and te… |
|
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Clinical-stage biotech developing dual-approach immuno-onco…
|
1541 | HK | Professional, scientific and te… |
|
IMMUNIC, INC.
Develops oral small molecule therapies for chronic inflamma…
|
IMUX | US | Professional, scientific and te… |
|
Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn anti…
|
IMVT | US | Professional, scientific and te… |
|
IMMUPHARMA PLC
Specialty biopharmaceutical company developing peptide-base…
|
IMM | GB | Professional, scientific and te… |
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
Jade Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33383/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33383 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33383 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33383 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33383}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Jade Biosciences, Inc. (id: 33383)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.